1 active not recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow Limb-girdle Muscular Dystrophy: new trials by email Literature Review of Limb-girdle Muscular Dystrophy trials Research Report on Limb-girdle Muscular Dystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 SRP-9003, Glucocorticoid - Limb-girdle Muscular Dystrophy | Phase 3 | Active not recruiting | Sarepta Therapeutics, Inc. | 17 | 2024-01-15 | 2026-03-02 |
| A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) Deflazacort - Limb-Girdle Muscular Dystrophy | Phase 3 | Terminated | PTC Therapeutics | 11 | 2019-10-31 | 2022-06-27 |
Muscular Dystrophies, Limb-Girdle (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Muscular Diseases (2) · Muscular Disorders, Atrophic (2) · Muscular Dystrophies (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2)
Glucocorticoids (1) · Prednisone (1) · deflazacort (1)
PTC Therapeutics (1) · Sarepta Therapeutics, Inc. (1)
Germany (2) · United States (2) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Italy (1) · Norway (1) · Russia (1) · Spain (1) · Sweden (1) · United Kingdom (1)